ClinicalTrials.gg
Not yet recruitingNCT07733713Updated Jul 29, 2026

Hysteroscopy and CD138+ Plasma Cell Density in Chronic Endometritis

An observational study in Chronic Endometritis, sponsored by Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita). Not yet recruiting. Open to female participants aged 18 Years to 46 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 46 Years
Sex
Female
01

Study summary

The goal of this observational study is to learn if a hysteroscopy exam alone can find chronic endometritis, a long-lasting inflammation of the lining of the uterus. A hysteroscopy is an exam that looks inside the uterus with a thin camera. Chronic endometritis is usually confirmed with a lab test that counts CD138-positive cells, a type of immune cell, in a small tissue sample from the uterus.

About 100 women will take part. All are already having a hysteroscopy and a tissue sample as part of their fertility care, often after repeated failed embryo transfers or repeated miscarriage.

The main question it aims to answer is:

Do the visual signs seen during hysteroscopy relate closely enough to the CD138 cell count to reliably find chronic endometritis without a lab test?

Participants will:

Have a hysteroscopy exam and a tissue sample from the uterus, both already part of their routine fertility care Have their hysteroscopy video reviewed by two doctors who do not know the tissue sample results Have their tissue sample checked in the lab for CD138 cells

Read the detailed description

Chronic endometritis (CE) is a persistent inflammation of the endometrial mucosa associated with recurrent implantation failure (RIF) and recurrent pregnancy loss (RPL). In clinical practice, CE is assessed using two complementary methods: office hysteroscopy, which identifies visual mucosal signs according to the Cicinelli criteria (micropolyps, focal hyperemia, diffuse hyperemia, stromal edema, strawberry pattern, and hemorrhagic spots), and immunohistochemical detection of CD138-positive (syndecan-1) endometrial plasma cells, considered the histopathological reference standard.

Published evidence comparing these two methods is inconsistent: individual studies, mostly retrospective, report weak agreement between hysteroscopic findings and plasma cell counts, while pooled diagnostic accuracy estimates suggest good hysteroscopic performance. This discrepancy is plausibly related to heterogeneous and non-comparable plasma cell count thresholds across studies, the use of dichotomized analyses that discard information, and retrospective designs prone to spectrum and verification bias. No prior study has characterized the relationship between hysteroscopic appearance and plasma cell burden as a continuous phenomenon.

This is a prospective, cross-sectional, single-center, non-pharmacological, non-device, no-profit observational study correlating an index test (hysteroscopy) with a reference standard (CD138 immunohistochemistry). Both tests are performed in the same session, so the interval between index test and reference standard is zero. The proliferative phase is standardized and confirmed histologically. Hysteroscopic and histopathological assessments are performed with reciprocal blinding, and there is no verification bias, as all participants undergo both the index test and the reference standard regardless of the hysteroscopic result.

Objectives and endpoints: The primary objective is to determine whether the number of hysteroscopic signs of CE correlates with the count of CD138-positive endometrial plasma cells, specifically testing whether this correlation is not clinically relevant (equivalence relative to a pre-specified negligible-effect threshold). The primary endpoint is the Spearman correlation coefficient between the CD138-positive plasma cell count (continuous variable) and the number of positive hysteroscopic signs (0-6), evaluated as an equivalence hypothesis against a pre-specified smallest effect size of interest (SESOI) of \|r\| \< 0.25, assessed with two one-sided tests (TOST) and complemented by a Bayes Factor quantifying the evidence in favor of the null hypothesis, together with the posterior probability that \|r\| is below the SESOI.

Secondary objectives are to characterize the association of each individual hysteroscopic sign with plasma cell burden; to quantify inter- and intra-observer reproducibility of hysteroscopic scoring and plasma cell counting; to describe the relationship between the indication for examination (RPL, RIF, or other) and both plasma cell burden and hysteroscopic findings; and, descriptively, to report participants' reproductive outcomes. Corresponding secondary endpoints include: the association of each hysteroscopic sign with plasma cell count; inter- and intra-observer agreement (kappa for hysteroscopy, intraclass correlation coefficient for plasma cell counting); diagnostic accuracy of hysteroscopy at conventional CD138 thresholds (≥1 and ≥5 plasma cells) as a secondary sensitivity analysis; the association between clinical indication and findings; and, descriptively, the rate of histological resolution after treatment (test-of-cure) and reproductive outcomes.

Population: Eligible participants are women of reproductive age undergoing office hysteroscopy with endometrial biopsy as part of their clinical work-up - including assisted reproduction (PMA) pathways - for any indication (RIF, RPL, or other), with the examination performed during the proliferative phase of a spontaneous cycle not exposed to exogenous progestins, and who provide written informed consent to participation and to data processing.

Procedures: Office hysteroscopy is performed vaginoscopically with saline distension, without anesthesia, during the early-to-mid proliferative phase of a spontaneous cycle. The endometrium is systematically inspected and scored for the six Cicinelli criteria, each recorded as present or absent, together with an overall hysteroscopic judgment of CE according to a pre-specified rule. Each procedure is fully video-recorded. Recordings are reviewed offline, independently and in random order, by two experienced hysteroscopists blinded to histology, clinical data, and each other's assessment; a random subsample is re-reviewed by the same observers after a pre-defined interval to estimate intra-observer agreement, with discordances resolved by consensus.

In the same session, an endometrial biopsy is obtained. Samples are formalin-fixed, paraffin-embedded, stained with hematoxylin-eosin, and processed for CD138 (syndecan-1) immunohistochemistry with positive and negative controls. CD138-positive stromal plasma cells, identified by unequivocal membranous positivity, are quantified by a pathologist blinded to hysteroscopic findings and all clinical data. Cycle phase is confirmed histologically by endometrial dating; in case of discordance between histological dating and cycle day, the sample is classified according to histological dating.

Patients with a histological diagnosis of CE receive first-line doxycycline 100 mg once daily for 15 days per standard clinical practice, followed by a test-of-cure endometrial biopsy after the next menstruation. Persistent CE is treated with second-line metronidazole and clindamycin, followed by a further biopsy. Cure is defined as a post-treatment plasma cell count below the primary diagnostic threshold. These procedures are part of routine clinical care and are not imposed by the study, which only observes and records them.

Statistical analysis: The primary endpoint (Spearman correlation) is analyzed under an equivalence hypothesis (SESOI \|r\| \< 0.25) using TOST, complemented by a Bayes Factor. Because a null correlation could reflect measurement error rather than true independence, reproducibility is quantified (Cohen's/Fleiss' kappa for hysteroscopic scoring; intraclass correlation coefficient for plasma cell counting), and an attenuation-corrected correlation is reported; interpretation of an equivalence result is conditional on adequate measurement reliability. Each individual hysteroscopic sign is compared with plasma cell count using the Mann-Whitney test. Plasma cell count is modeled as an overdispersed count variable via negative binomial regression, with hysteroscopic signs as predictors and age, clinical indication, and cycle day as covariates. Analyses stratified by indication, and any sign-by-indication interaction, are pre-specified as exploratory. Diagnostic accuracy of hysteroscopy at CD138 thresholds of ≥1 and ≥5 plasma cells (sensitivity, specificity, predictive values) is reported as a secondary sensitivity analysis. The significance level is set at 0.05 (two-sided). The detailed statistical analysis plan is time-stamped and deposited on the Open Science Framework before the primary analysis is performed.

Sample size: Approximately 100 participants will be enrolled, sized to provide adequate precision for the primary equivalence analysis with SESOI \|r\| \< 0.25 (power approximately 80%). With this sample size, an observed correlation near zero yields a 95% confidence interval excluding correlations stronger than approximately 0.20 in either direction. Analyses of individual low-prevalence signs and of the indication interaction are pre-specified as exploratory and hypothesis-generating. Approximately 20 patients already evaluated before study initiation are treated as a separate pilot cohort and are not included in the prospectively registered case series.

Ethics and data management: The study is conducted in accordance with the Declaration of Helsinki and applicable good clinical practice standards, and initiation is contingent on a favorable opinion from the competent Ethics Committee. All participants provide written informed consent to participation and, separately, to personal data processing under Regulation (EU) 2016/679. The study does not add invasive procedures beyond routine clinical care: hysteroscopy, biopsy, CD138 immunohistochemistry, and post-treatment control biopsies are part of standard practice; the study adds only standardized scoring, blinded re-reading of video recordings, and systematic data collection, with no additional burden for participants or the health service. Data are collected in pseudonymized form via a study identification code; the code-identity correspondence table is stored separately and securely, accessible only to authorized personnel.

Registration and reporting: The study is prospectively registered on ClinicalTrials.gov before enrollment begins. The statistical analysis plan is time-stamped and deposited on the Open Science Framework. Reporting will follow the STARD and STROBE guidelines. Results will be submitted for publication in a peer-reviewed journal regardless of outcome direction. The study is non-profit and entirely funded by Centro A.M.B.R.A., with no external sponsors; investigators declare no relevant conflicts of interest.

02

Conditions studied

  • Chronic Endometritis

Browse trials for

Keywords

  • CD138
  • Endometrial Plasma Cells
  • Syndecan-1
  • Hysteroscopy
  • Diagnostic Accuracy
  • Recurrent Implantation Failure
  • Recurrent Pregnancy Loss
03

In context

Endometritis

50 studies on the registry are indexed under Endometritis; 11 are open to participants now.

Browse Endometritis studies →

Lead sponsor

Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 46 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women aged 18-46 years referred for office hysteroscopy with endometrial biopsy at Centro A.M.B.R.A. (Palermo, Italy), for any clinical indication including recurrent implantation failure, recurrent pregnancy loss, or other reasons. All examinations are performed during the early-to-mid proliferative phase (cycle days 6-12) of a spontaneous, non-progestin-exposed menstrual cycle. Approximately 100 participants will be prospectively enrolled and registered; an additional approximately 20 patients evaluated before study initiation constitute a separate pilot cohort and are not included in this population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman aged 18-46 years undergoing office hysteroscopy with endometrial as part of her clinical work-up (including assisted reproduction/PMA pathways), for any indication (recurrent implantation failure, recurrent pregnancy loss, or other).
  • Examination performed during the early-to-mid proliferative phase (cycle days 6-12) of a spontaneous cycle not exposed to exogenous progestins
  • Written to participation and to data processing

Exclusion criteria

Exclusion Criteria:

  • Current or suspected pregnancy
  • status
  • Clinically active pelvic or lower genital tract infection
  • Systemic antibiotic use within the preceding 4 weeks
  • Use of exogenous progestins or other hormonal therapy within the preceding 4 weeks
  • Submucous myoma, endometrial polyp, or synechiae precluding reliable
  • assessment of the endometrial surface
  • Inability to obtain adequate endometrial tissue for immunohistochemistry
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Spearman correlation between CD138-positive endometrial plasma cell count and number of positive hysteroscopic signs of chronic endometritis

    Correlation (Spearman's rho) between the count of CD138-positive endometrial stromal plasma cells, quantified by immunohistochemistry as a continuous variable, and the number of positive hysteroscopic signs among the six Cicinelli criteria (range 0-6). The primary hypothesis is one of equivalence: the true correlation is hypothesized to fall within a pre-specified smallest effect size of interest (SESOI) of \|r\| \< 0.25. Equivalence is assessed using two one-sided tests (TOST) and complemented by a Bayes Factor quantifying the evidence in favor of the null hypothesis, together with the posterior probability that \|r\| is below the SESOI.

    Time frame: Baseline - single time point; hysteroscopy and endometrial biopsy are performed in the same clinical session, so the interval between index test and reference standard is zero

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Nov 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Jul 29, 2026
StartEst.
Sep 14, 2026
Primary completionEst.
Nov 26, 2026
CompletionEst.
Nov 26, 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07733713
Lead sponsor
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Sep 14, 2026 (estimated)
Primary completion
Nov 26, 2026 (estimated)
Completion
Nov 26, 2026 (estimated)
Last update
Jul 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion